JMP Securities Reiterates Market Outperform on Ambrx Biopharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Ambrx Biopharma (NASDAQ:AMAM) and maintained a price target of $15.

November 20, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin reaffirmed a 'Market Outperform' rating on Ambrx Biopharma with a $15 price target, indicating a positive outlook for the stock.
The reiteration of a 'Market Outperform' rating and the maintenance of a $15 price target by a reputable analyst like Reni Benjamin could instill confidence in investors and positively influence Ambrx Biopharma's stock price in the short term. The specific mention of the company and the reaffirmation of the price target suggest a strong conviction in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100